Bruce Tobin is asking Health Canada to approve psilocybin to treat anxiety and depression in end-of-life patients.
FDA approval for psilocybin-assisted therapy for depression appears to be on the horizon.
Researchers push to move psilocybin from Schedule I to Schedule IV if Phase III clinical trials are successful.
The FDA will work to expedite the development and review of the drug so it can get to patients as soon as possible.
Researchers measured the effects of psilocybin by comparing brain scans.